Exelon, also known as rivastigmine, is a medication with the active ingredient rivastigmine tartrate. It is used to treat mild to moderate dementia related to Alzheimer’s disease and Parkinson’s disease. Exelon helps improve memory, awareness, and the ability to perform daily functions.
The fiscal range for Exelon stands at £0.48 to £1.28 per pills. The crux of the pricing revolves around pack dimensions and ingredient quality (30 or 360 mg).
Exelon
Rivastigmine
Cholinesterase Inhibitors
Available in capsule form in strengths of 1.5 mg, 3 mg, 4.5 mg, and 6 mg. Additionally, available in a transdermal patch with doses releasing 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours.
Indicated for the treatment of mild to moderate dementia associated with Alzheimer’s disease and Parkinson’s disease.
Inhibits acetylcholinesterase and butyrylcholinesterase, thereby increasing levels of acetylcholine in the brain, which is involved in cognitive processes.
The starting dose for capsules is typically 1.5 mg twice a day, with gradual increases to a maintenance dose of 6-12 mg per day, based on patient tolerability. For the transdermal patch, initial dosing generally starts at 4.6 mg/24 hrs and can be increased to 9.5 mg/24 hrs and then to 13.3 mg/24 hrs based on needs and tolerability.
Capsules should be taken with meals, twice daily, to reduce gastrointestinal side effects. The transdermal patch should be applied to clean, dry, hairless skin on the upper or lower back, upper arm, or chest, and replaced every 24 hours.
No dosage adjustments are required for patients with mild to moderate renal impairment. However, use with caution in patients with severe renal impairment.
Dosage adjustments are not necessary for mild to moderate hepatic impairment, but caution is advised in those with severe hepatic impairment.
Nausea, vomiting, diarrhea, weight loss, dizziness, and loss of appetite. Transdermal patches may cause localized skin reactions at the application site.
Rivastigmine may interact with anticholinergic medications, potentially diminishing their effects. Co-administration with beta-blockers or other agents affecting heart rate may increase the risk of bradycardia. Use caution when prescribing with antipsychotics or muscle relaxants.
Use with increased caution in elderly patients, as they may be more susceptible to side effects such as dizziness or bradycardia. Safety and efficacy in pediatric populations have not been established.
Contraindicated in patients with known hypersensitivity to rivastigmine, carbamate derivatives, or any component of the formulation. Also contraindicated in patients with severe hepatic impairment.
Capsules should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). Transdermal patches should be stored at room temperature and protected from excessive heat and moisture.
Patients should be advised to take capsules with meals and ensure proper adherence to dosing schedules. Instruct on correct application of transdermal patches and the importance of rotating application sites. Inform them about the potential side effects and the need to report any severe or persistent symptoms to their healthcare provider.
Regular monitoring of cognitive function and behavioral symptoms is recommended to assess the effectiveness of the treatment. Periodic assessment of body weight is advised due to the potential for significant weight loss.
Further surveillance and reporting of adverse effects observed in clinical practice are essential for ongoing safety evaluation. Health care providers should report any suspected adverse reactions to relevant regulatory authorities.
Clinical trials have demonstrated that rivastigmine provides modest improvements in cognitive function and daily living activities in patients with Alzheimer’s and Parkinson’s Disease. Improved outcomes were observed when patient adherence to treatment was maintained over the long term.